Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manfred Kaufmann

Showing results (111-120 of 141) with videos related to

Pageof 15
Sort By:
Cancer|December 13, 2005
Breast carcinoma during pregnancy. International recommendations from an expert meetingSibylle Loibl, Gunter von Minckwitz, Karin Gwyn, et al.
Human Pathology|January 24, 2006
C-KIT expression in ductal carcinoma in situ of the breast: co-expression with HER-2/neuRaihanatou Diallo, Achim Rody, Christian Jackisch, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 29, 2011
The GISS trial: a phase II prevention trial of screening plus goserelin, ibandronate, versus screening alone in premenopausal women at increased risk of breast cancerGunter von Minckwitz, Sibylle Loibl, Christian Jackisch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2007
Poor outcome in estrogen receptor-positive breast cancers predicted by loss of plexin B1Achim Rody, Uwe Holtrich, Regine Gaetje, et al.
Plos One|January 6, 2012
Homogeneous datasets of triple negative breast cancers enable the identification of novel prognostic and predictive signaturesThomas Karn, Lajos Pusztai, Uwe Holtrich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2005
Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast GroupGunter von Minckwitz, Günter Raab, Angelika Caputo, et al.
European Journal of Cancer (Oxford, England : 1990)|July 12, 2011
Melanoma antigen family A identified by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentationThomas Karn, Lajos Pusztai, Eugen Ruckhäberle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2004
Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancerAlan M Keller, Robert G Mennel, Vassilis A Georgoulias, et al.
Clinical Breast Cancer|November 12, 2002
Dose-dense biweekly doxorubicin/docetaxel versus sequential neoadjuvant chemotherapy with doxorubicin/cyclophosphamide/docetaxel in operable breast cancer: second interim analysisChristian Jackisch, Gunter von Minckwitz, Holger Eidtmann, et al.
Breast Cancer Research : BCR|September 20, 2005
Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomasGunter von Minckwitz, Sebastian Harder, Sascha Hövelmann, et al.
Pageof 15

Showing results (111-120 of 141) with videos related to

Sort By:
Pageof 15
Cancer|December 13, 2005
Breast carcinoma during pregnancy. International recommendations from an expert meetingSibylle Loibl, Gunter von Minckwitz, Karin Gwyn, et al.
Human Pathology|January 24, 2006
C-KIT expression in ductal carcinoma in situ of the breast: co-expression with HER-2/neuRaihanatou Diallo, Achim Rody, Christian Jackisch, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 29, 2011
The GISS trial: a phase II prevention trial of screening plus goserelin, ibandronate, versus screening alone in premenopausal women at increased risk of breast cancerGunter von Minckwitz, Sibylle Loibl, Christian Jackisch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2007
Poor outcome in estrogen receptor-positive breast cancers predicted by loss of plexin B1Achim Rody, Uwe Holtrich, Regine Gaetje, et al.
Plos One|January 6, 2012
Homogeneous datasets of triple negative breast cancers enable the identification of novel prognostic and predictive signaturesThomas Karn, Lajos Pusztai, Uwe Holtrich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2005
Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast GroupGunter von Minckwitz, Günter Raab, Angelika Caputo, et al.
European Journal of Cancer (Oxford, England : 1990)|July 12, 2011
Melanoma antigen family A identified by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentationThomas Karn, Lajos Pusztai, Eugen Ruckhäberle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2004
Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancerAlan M Keller, Robert G Mennel, Vassilis A Georgoulias, et al.
Clinical Breast Cancer|November 12, 2002
Dose-dense biweekly doxorubicin/docetaxel versus sequential neoadjuvant chemotherapy with doxorubicin/cyclophosphamide/docetaxel in operable breast cancer: second interim analysisChristian Jackisch, Gunter von Minckwitz, Holger Eidtmann, et al.
Breast Cancer Research : BCR|September 20, 2005
Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomasGunter von Minckwitz, Sebastian Harder, Sascha Hövelmann, et al.
Pageof 15